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Abstract  
The Progression and Impact of Sleep Disordered Breathing in Acutely Decompensated 
Heart Failure Post-Discharge 
 
Background: Sleep disordered breathing (SDB) is prevalent in more than half of patients with 
stable heart failure (HF). The Ohio State University Medical Center (OSUMC) Ross Heart 
Hospital has implemented a surveillance program to identify and treat sleep disordered 
breathing (SDB) in patients admitted with acutely decompensated heart failure (ADHF). 
Problem Statement: No studies have examined SDB following treatment during ADHF 
admission in-hospital to outcomes post-discharge.  Purpose: To evaluate the effectiveness and 
feasibility of the in-hospital screening program at the Ross Hospital and evaluate the course of 
SDB post-discharge for admittance of ADHF. Methods: Subjects were obtained from an 
existing database of sleep study reports for ADHF admittance between May and September 
2010. Patients were contacted by mail with a Minnesota Living with Heart Failure (MLWHF) 
questionnaire and a letter of instruction. All received a phone call inquiring about their follow-up 
status as well as an educational session about SDB and their heart condition. Patients were 
also asked to complete the questionnaire over the phone if they did not mail their responses. 
Results: 105 patients qualified for the in-hospital screening. 17 (16%) were negative for SDB 
and 88 (84%) were positive for SDB. Patients negative for SDB scored a MLWHF mean of 
23.50 and patients positive for SDB had a mean score of 35.98. Of the 105 patients, 70 (67%) 
confirmation letters of SDB diagnosis were sent. In a separate cohort of 36 patients identified 
with CSA in-hospital, 26 of 36 (77%) identified with CSA on repeat studies post-discharge with 
optimal medical therapy. Conclusion: This study confirms the high prevalence of SDB in 
ADHF. While this study showed no significance in quality of life between SDB cohorts, the 
difference may be clinically significant for post-discharge outcomes. Screening has greater 
implications of expedited treatment of SDB during ADHF hospitalizations.  
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Chapter I: Introduction 
Heart failure (HF) is related to increasing incidence and steady related mortality with little 
improvement demonstrated over time [1, 2]. HF affects 5 million Americans and is the most 
common Medicare diagnosis upon discharge [3]. For 2010, the annual cost of HF was estimated 
to exceed $39.2 billion [4]. Utilization and hospitalization costs are notably higher in the elderly 
population presenting with acutely decompensated heart failure (ADHF) [3]. Hospital 
readmission rates remain high with almost 50% readmission within six months of discharge [5, 
6].  While there have been promising advancements in pharmacologic practice guidelines, 
treatment options for ADHF still remain relatively unchanged [7]. Due to increasing morbidity, 
mortality and economic burdens associated with ADHF, it is imperative to study and address co-
morbid factors as an adjunct to conventional treatments.  
 
Sleep disordered breathing (SDB) is categorized into obstructive sleep apnea (OSA) and central 
sleep apnea (CSA). During OSA, collapsing of the pharyngeal airway causes increased 
negative intrathoracic pressure with cyclical episodes of intermittent hypoxia and surges of 
sympathetic activity [8, 9]. Increased activation of the sympathetic system in OSA is strongly 
associated with hypertension [10, 11]. The intermittent hypoxia pattern seen in OSA as well as 
CSA is linked to endothelial dysfunction and atherosclerosis [12]. Therefore it is likely that the 
cardiovascular consequences of OSA would worsen heart failure and may promote 
decompensation. The occurrence of CSA is predominantly specific to HF [13], where CSA 
presents with a cyclic pattern hypoventilation and hyperventilation known as Cheyne-Stokes 
respiration (CSA-CSR).  The presence of CSA in heart failure patients is linked to worsened 
outcomes. This is likely due to mechanisms similar to those of OSA. Both sleep disorders are 
associated with the same pattern of intermittent hypoxia and sympathetic activation. The use of 
positive airway pressure (PAP) therapy for SDB in HF has shown positive effects on cardiac 
markers such as left ventricular function, blood pressure, and heart rate [14-17]. 
 
The Ohio State University Medical Center (OSUMC) Ross Heart Hospital has implemented a 
surveillance program to identify SDB in patients admitted with ADHF for better initiation of 
treatment. Earlier findings in this program showed improved left ventricular function within days 
of PAP therapy for SDB in-hospital [17]. An evaluation of this program’s feasibility is essential 
for enhanced management of HF and has significant implications towards a standardization of 
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care for SDB in ADHF admissions. This project is designed to examine the impact of SDB on 
post-discharge outcomes in patients with ADHF.  
 
Aim 1- To evaluate an in-hospital program for the diagnosis of SDB 
1a- Determine feasibility of in-house screening program for patients with SDB. 
 We would expect a high prevalence of OSA and CSA in patients screened for 
SDB in-hospital.  
 1b- Perform a quality program of an existing program tasked with screening 
hospitalized patients.  
 We would expect a lack of follow-up post-discharge which would result in 
less patients on treatment for their SDB. 
 We would expect patients with SDB to have a higher morbidity and poorer 
quality of life (higher questionnaire score) than patients negative for SDB.  
Aim 2- To evaluate the natural course of CSA in the post-discharge period in patients admitted 
with ADHF. 
 We would expect decreased central events in the post-discharge phase. 
Chapter II: Literature Review 
SDB is more common in HF patients than in the general middle-aged adult population [18] with 
several studies showing a high prevalence of both OSA (40-57%) and CSA (15-40%) [14, 19-
21]. All of these studies were performed on stable heart failure subjects with varying cut-off 
criteria in the outpatient setting. OSA and CSA are associated with a similar profile of 
cardiovascular consequences that worsen heart failure. Both are associated with a pattern of 
intermittent hypoxia that results in sympathetic activation and increases in blood pressure [22] 
[23]. OSA exacerbates existing cardiovascular disease and increases associated cardiovascular 
events [24-26]. In hypertensive patients, OSA worsens blood pressure control [27, 28]. Patients 
with OSA have increased risk of developing atrial fibrillation [29, 30], and recurrence after 
cardioversion [30]. OSA also increases the risk of developing coronary artery disease (CAD) 
[31] and worsened outcomes [32, 33]. The cardiac consequences of OSA are most notably 
linked to sympathetic activation [34, 35] and are shown to negatively impact HF patients [36-38] 
by exacerbating hypertension[39, 40], CAD[41-43], and arrhythmia[44, 45]. These symptoms 
and conditions are known to cause acute HF [46]. Therefore, severe sympathetic activation 
would exacerbate existing heart failure and cause ADHF. Similarly, CSA is also associated with 
increased sympathetic activity and risk of cardiac arrhythmia [47]. Periodic breathing in CSA 
causes increased negative intrathoracic pressure, which affects afterload and subsequent 
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precipitation of pulmonary edema [48]. This has implications for worsening cardiac function and 
readmissions. 
 
A recent study of Medicare beneficiaries with heart failure revealed that less than 4% are ever 
diagnosed with SDB and those who were screened earlier in their diagnosis showed better 
survival [49]. Coupled with current underutilization of SDB screening and subsequent treatment, 
a recent study of inpatients with ADHF showed 75% prevalence of SDB [50]. These studies 
emphasize the necessity and importance of an in-hospital screening program for expedited 
treatment of SDB in ADHF. Treatment of concurrent OSA in patients with heart failure carries 
promising positive impact on morbidity and mortality. The beneficial effects of PAP therapy in 
HF patients with OSA are well supported. Continuous positive airway pressure (CPAP) on 
patients with OSA and HF decreases nocturnal heart rate, systolic blood pressure and AHI [14]. 
Combined PAP therapy and medical therapy showed a significant improvement of LVEF 
compared to only medical therapy [15, 16].  
 
Treatment of CSA with CPAP has also shown significant improvement in LVEF in CHF [51-53]. 
In one of the largest and longest studies of CSA and HF, there was an improvement in LVEF, 
norepinephrine levels, and six minute walk on treatment with PAP [51]. PAP therapy is likely to 
reverse symptoms[54]. Therefore, diagnosis and treatment of SDB is likely to improve the 
outcome of patients with heart failure. To date, there is no standard of practice for systematic 
approach to diagnosis and treatment of OSA in patients with stable HF, much less ADHF [55-
57]. It is possible that patients with ADHF are more susceptible for the impact of SDB on their 
cardiac function [17]. No study has evaluated an inpatient screening program of ADHF or 
studied the impact of SDB on ADHF outcomes.   
 
It is probable that the impact of SDB on HF is most pronounced in the immediate post-discharge 
phase. Within the first month, HF patients have six times the risk for sudden mortality and they 
experience high rehospitalization rates within the first six months [1, 6]. Untreated OSA in HF 
demonstrates higher mortality than patients treated for SDB [49, 58]. To date, no evaluation 
exists regarding the impact of SDB on HF related symptoms in the post-discharge phase. The 
appropriate methods and sample size for such an evaluation have not been establishedCSA 
severity and prevalence may correlate with HF [47, 59]. CSA may be a consequence of heart 
failure [59] linked with increased chemosensitivity to CO2 [60] and pulmonary congestion [47]. 
Patients with heart failure may manifest a mixed sleep disorder with features of both OSA and 
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CSA. Visualizations of modeled central events demonstrated obstructive components with 
central events [61]. Therefore, it is possible that CSA events will decrease with optimal 
management of heart failure in the post-discharge phase [62].The treatment for CSA and OSA 
is accomplished by different positive pressure devices in the outpatient setting. It is important to 
differentiate components of SDB in the inpatient setting and confirm the persistence of CSA in 
the outpatient setting.   
Chapter III: Methodology 
Data was obtained from portable sleep studies performed at the OSUMC Ross Heart Hospital 
for ADHF admission between May and September 2010. Admitted patients met the following 
eligibility requirements: a diagnosis of congestive heart failure and elevated left ventricular 
pressure as indicated by at least one sign and one symptom of volume overload (pedal edema, 
crackles, consistent chest X-ray, increased left ventricular end-diastolic dimension (LVEDD), or 
elevated B-type natriutic peptide (BNP) level. All patients had previously unidentified sleep 
apnea with an AHI > 15 events per hour and received treatment for heart failure that included IV 
diuretics, IV infusion of inotropes, vasodilators, planned revascularization, or device therapy. 
Conventional scoring mechanisms were utilized to determine patients’ risks for SDB. In addition 
to verbal confirmation of their SDB status, patients received a letter post-discharge of whether 
they were positive or negative for SDB with instructions and options for follow-up. Additionally, a 
separate CSA cohort was reviewed for a sensitivity comparison of in-patient sleep tests and out-
patient overnight polysomnography test (PSG).  
Study Protocols 
Subjects were identified from an ongoing database of sleep study reports for ADHF admissions. 
All patients were initially contacted via mail with a Minneosta Living with Heart Failure (MLWHF) 
Questionnaire (Appendix A) and a letter of instruction. MLWHF questionnaire has been 
validated to describe the impact of HF severity on quality of life [63-67]. In multiple randomized 
controlled trials of pharmacological interventions in HF, the MLWHF questionnaire improved 
from 3-12 points over periods of three to six months, thus reflecting effectiveness of the 
intervention [67-69].  
 
Upon completion of the questionnaire, patients were encouraged to contact the office for further 
follow-up of results. Phone calls followed an algorithm of triage (Appendix B) dependent on the 
results of their initial sleep study, follow-up status and questionnaire completion. If patients 
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screened positive for SDB on their initial sleep test and expressed no follow-up for sleep apnea 
since discharge, they received an educational session about the risks of SDB and their heart 
failure along with the importance of a PSG. If no questionnaire was received, the questionnaire 
was administered over the phone. For patients who were unreachable, at least two attempts 
were made to contact the patient.  
A separate cohort of patients was identified in-hospital with CSA between 2007 and 2010. All 
patients received an in-patient sleep study and a repeat study post-discharge. We compared 
both studies for sensitivity of in-patient and out-patient screening.  
Statistical Analysis 
Descriptive statistics such as means, medians, and ranges were used to characterize patient 
demographic data. Frequencies were utilized to determine the most common reasons for 
unreachable patients and lack of follow-up. T-tests were used to identify significance of SDB 
cohort characteristics and questionnaire scores.   
Chapter IV: Article   
Introduction 
Heart failure (HF) continues to have high increasing incidence and steady related mortality with 
little improvement [1, 2]. HF affects 5 million Americans and is the most common Medicare 
diagnosis upon discharge [3]. For 2010, the annual cost of HF was estimated to exceed $39.2 
billion [4]. Utilization and hospitalization costs are notably higher in the elderly population 
presenting with acutely decompensated heart failure (ADHF) [3]. Hospital readmission rates 
remain high with almost 50% readmission within six months of discharge [5, 6]. While there 
have been promising advancements in pharmacologic practice guidelines, treatment options for 
ADHF still remain relatively unchanged [7]. Due to increasing morbidity, mortality and economic 
burdens associated with ADHF, it is imperative to study and address co-morbid factors as an 
adjunct to conventional treatments.  
 
Sleep disordered breathing (SDB) is categorized into obstructive sleep apnea (OSA) and central 
sleep apnea (CSA). SDB is more common in HF patients than in the general middle-aged adult 
population [18] with several studies showing a high prevalence of both OSA  (40-57%) and CSA 
(15-40%) [14, 19-21]. OSA and CSA are associated with a similar profile of cardiovascular 
consequences that worsen heart failure. CSA severity and prevalence may correlate with HF 
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[47, 59]. CSA may be a consequence of heart failure [59] linked with increased chemosensitivity 
to CO2 [60] and pulmonary congestion [47]. Both sleep disorders are associated with the same 
pattern of intermittent hypoxia and sympathetic activation. The use of positive airway pressure 
(PAP) therapy for SDB in HF has shown positive effects on cardiac markers such as left 
ventricular function, blood pressure, and heart rate [14-17]. Treatment for CSA and OSA is 
accomplished by different positive pressure devices in outpatients. Therefore it is important to 
differentiate components of SDB in the inpatient setting and confirm the persistence of CSA in 
the outpatient setting.   
 
A recent study of Medicare beneficiaries with heart failure revealed that less than 4% are ever 
diagnosed with SDB and those who were screened earlier in their diagnosis showed better 
survival [49]. Coupled with current underutilization of SDB screening and subsequent treatment, 
a recent study of inpatients with ADHF showed 75% prevalence of SDB [50]. These studies 
emphasize the necessity and importance of an in-hospital screening program for expedited 
treatment of SDB in ADHF. 
 
The Ohio State University Medical Center (OSUMC) Ross Heart Hospital has implemented a 
surveillance program to identify SDB in patients admitted with ADHF for better initiation of 
treatment. Earlier findings in this program showed improved left ventricular function within days 
of PAP therapy for SDB in-hospital [17]. An evaluation of this program’s feasibility and 
effectiveness is essential for enhanced management of HF and has significant implications 
towards a standardization of care for SDB in ADHF admissions. This project is designed to 
examine the impact of SDB on post-discharge outcomes in patients with ADHF. No study has 
evaluated an inpatient screening program of ADHF or studied the impact of SDB on ADHF 
outcomes.   
 
Methodology 
Data was obtained from portable sleep studies performed at the OSUMC Ross Heart Hospital 
for ADHF admission between May and September 2010. Admitted patients met the following 
eligibility requirements: a diagnosis of congestive heart failure and elevated left ventricular 
pressure as indicated by at least one sign and one symptom of volume overload (pedal edema, 
crackles, consistent chest X-ray, increased left ventricular end-diastolic dimension (LVEDD), or 
elevated B-type natriuretic peptide (BNP) level. All patients had previously unidentified sleep 
apnea with an AHI > 15 events per hour and received treatment for heart failure that included IV 
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diuretics, IV infusion of inotropes, vasodilators, planned revascularization, or device therapy. 
Conventional scoring mechanisms were utilized to determine patients’ risks for SDB. In addition 
to verbal confirmation of their SDB status, patients received a letter post-discharge of whether 
they were positive or negative for SDB with instructions and options for follow-up. Additionally, a 
separate CSA cohort was reviewed for a sensitivity comparison of in-patient sleep tests and out-
patient overnight polysomnography test (PSG).  
Study Protocols 
Subjects were identified from an ongoing database of sleep study reports for ADHF admissions. 
All patients were initially contacted via mail with a Minnesota Living with Heart Failure (MLWHF) 
Questionnaire and a letter of instruction. MLWHF questionnaire has been validated to describe 
the impact of HF severity on quality of life [63-67]. In multiple randomized controlled trials of 
pharmacological interventions in HF, the MLWHF questionnaire improved from 3-12 points over 
periods of three to six months, thus reflecting effectiveness of the intervention [67-69]. Upon 
completion of the questionnaire, patients were encouraged to contact the office for further 
follow-up of results. Phone calls followed an algorithm of triage dependent on the results of their 
initial sleep study, follow-up status and questionnaire completion. If patients screened positive 
for SDB on their initial sleep test and expressed no follow-up for sleep apnea since discharge, 
they received an educational session about the risks of SDB and their heart failure along with 
the importance of a PSG. If no questionnaire was received, the questionnaire was administered 
over the phone. For patients who were unreachable, at least two attempts were made to contact 
the patient.  
A separate cohort of patients was identified in-hospital with CSA between 2007 and 2010. All 
patients received an in-patient sleep study and a repeat study post-discharge. We compared 
both studies for sensitivity of in-patient and out-patient screening.  
Statistical Analysis 
Descriptive statistics such as means, medians, and ranges were used to characterize patient 
demographic data. Frequencies were utilized to determine the most common reasons for 
unreachable patients and lack of follow-up. T-tests were used to identify significance of SDB 
cohort characteristics and questionnaire scores.   
Results 
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Patient Characteristics 
105 patients qualified for the in-hospital screening between May and September 2010.  The 
breakdown was as follows: 25 females (23.8%), 80 males (76.2%) from 25-86 years of age and 
a mean ejection fraction (EF) of 34%. Of these patients screened in-hospital, 17 (16%) were 
negative for SDB and 88 (84%) were positive for SDB. See Table 1 for a detailed breakdown for 
SDB prevalence. During the evaluation, 10 passed away and two were excluded due to 
incarceration. Of the remaining 93 patients, 62 were successfully contacted by the researcher 
via phone (Figure 1). The most common reasons for not reaching patients were due to 
disconnected or out-of-service phone numbers or the patient was unavailable at the time of the 
call.  
Follow-up  
A retrospective analysis of the conformation letter indicated 70 (67%) documented letters were 
mailed to patients. Of those reached by phone, 20 (32%) indicated follow-up either with their 
cardiologist, primary care provider, and or with a PSG (Figure 1). The most common reasons for 
lack of follow-ups were pending appointments or disinterest. Seven stated that they were 
currently on treatment for SDB. While 93 patients were mailed questionnaires, we received 61 
MLWHF questionnaires in the mail and over the phone. Some patients mailed in their 
questionnaires but could not be reached due to unserviceable phone numbers. There was no 
significant difference in age (p value= .469), AHI (p value= .227), and BMI (p value= .126) of 
responders and non-responders of the MLWHF questionnaire (Table 2). Those who were 
negative for SDB had a mean MLWHF score of 23.5 (n=11) while patients with SDB had a 
mean MLWHF score of 36 (n=50). There was no significance (p value = .218) between 
response scores (Table 3).  
Central Sleep Apnea 
Between 2007 and 2010, 36 patients were initially identified with CSA in-hospital. Of these 
patients, 26 (77%) were identified with CSA on repeat studies six months average post-
discharge. 8 were identified with OSA and 2 were negative for SDB.  
Discussion 
To date, no study has reviewed an in-patient program tasked to identify SDB in ADHF with 
outcomes post-discharge. Between May and September 2010, 84% of the 105 patients 
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screened in-hospital tested positive for SDB. Of those patients with SDB, the majority 
demonstrated predominantly OSA (62%) with a minority of CSA (13%) and mix of both central 
and obstructive events (1%). This supports the results of Khayat et al [50] in which 75% of 
hospitalized patients demonstrated SDB as well as Paulino et al who found 81% prevalence of 
SDB in the same population [70]. An earlier study by Javaheri [20] found that 40% of heart 
failure patients had CSA and 11% had OSA.  Sin et al [71] also found a similar break down of 
SDB categories. Both authors evaluated predominantly elderly male populations. More recent 
studies [19-21, 71] have demonstrated a predominance of OSA compared to CSA. OSA is 
highly prevalent in the non-heart failure population and its predominance in the heart failure may 
be explained by aging and increased BMI in these patients [71]. Earlier findings of in-hospital 
screening revealed that patients screened for OSA during hospitalization were 100% predictive 
of having OSA on repeat outpatient studies [50]. The presence of CSA may be related to the 
severity of HF [47], and is rarely seen outside of heart failure population. Treatment of heart 
failure improves but does not eliminate CSA [62].Therefore, it is important to determine whether 
having CSA in the inpatient setting correlates with persistence of this disorder in the outpatient 
setting.  
Currently little is known about follow-up and treatment for SDB from the in-patient to out-patient 
setting. Despite a 60% response by phone and questionnaire, there was no difference in age, 
BMI, or AHI between responders and non-responders. A retrospective analysis of initial SDB 
letters notes a 67% correspondence with discharged patients and subsequent follow-up of 32% 
three to six months post-discharge. While not all patients were initially contacted with their SDB 
status, it remains unclear as to whether the patients themselves were aware of their risks for 
SDB despite notification by letter. Modifications are needed to improve the efficiency of follow-
up in this program. Patient follow-up may include barriers such as no insurance or insufficient 
patient education regarding the consequences of SDB and its implications for their heart failure.  
In terms of quality of life in the post-discharge phase, there was no statistically significant 
difference (p = .218) in mean MLWHF scores between patients positive and negative for SDB. A 
lack of statistical significance may have been due to a small sample size and does not rule out a 
clinically significant difference of 12.48 points between SDB groups. The presence of 
comorbidities such as periodic limb movements and depression may explain a wide range in 
scores, particularly in the negative SDB group. This may have resulted in an elevation of 
questionnaire scores due to the effects of their comorbidities on their daily living instead of their 
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HF. Patients were not screened for these conditions and were not excluded in the overall 
analysis.    
Despite optimal medical therapy for HF, this study demonstrated a 76% prevalence of CSA on 
repeat sleep studies more than six months post-discharge. CSA is rationalized as a 
consequence of HF severity [48] with worsening congestion and pulmonary capillary wedge 
pressure [47]. A study by Tamura et al [72] showed that the use of beta-blockers decreased 
central events. Similarly, Solin et al found that treatment of heart failure with diuresis can 
decrease the number of central events [47]. Therefore with optimized medical therapy, the 
prevalence of CSA was thought to decline in the outpatient phase with proper management. 
These findings support the notion that new treatment guidelines for heart failure has resulted in 
decreased prevalence of CSA. Secondly, the persistence of CSA has shown that CSA 
diagnoses in-hospital is a chronic disease state that can be targeted with specific interventions. 
This has further implications for individualized treatment and management of CSA in the 
outpatient setting.   
In conclusion, this study confirms a high prevalence of SDB in patients hospitalized for ADHF. 
While there was no statistically significant difference between mean MLWHF scores, patients 
with SDB trended towards worsened quality of life. A larger sample is needed to detect 
differences in quality of life between SDB cohorts. While only two thirds of patients in this 
program were notified of their SDB diagnosis post-discharge, this contrasts a 4% diagnosis rate 
in a large cohort of Medicare beneficiaries [49]. More importantly, this study supports the 
necessity of surveillance programs for screening and expedited treatment of SDB in ADHF.  
Chapter V: Discussion & Conclusion 
According to a recent study by Javaheri et al [49] only 4% of medicare patients with newly 
diagnosed HF were suspected of SDB and only 2% received screening. The current state of 
screening and treatment for SDB in HF remains underutilized despite a high prevalence of SDB 
in this population [19-21, 71]. Compared nationally, 32% of patients screened by the program 
indicated follow-up post-discharge. Correspondence with patients could be improved with 
increased support and resources for a systematic implementation of communication and follow-
up. Services such as appointment scheduling prior to discharge or phone calls post-discharge 
would encourage patients to follow-up and seek treatment. Patient education may also improve 
follow-up by offering educational materials in-hospital. Therefore, patients will be more informed 
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of the health consequences related to SDB and the importance of addressing this in the 
outpatient setting.  
The use of the MLWHF questionnaire could be administered to larger samples to determine a 
difference in patients’ quality of life with and without SDB. However, these tools are potentially 
misleading due to comordibities such as periodic limb movements and depression. These 
comobidities may alter patients’ responses of their day-to-day experiences. Exclusion criteria 
should be further defined to account for these conditions. The evaluation could be extended to 
include additional markers such as readmission and six-minute walk. These markers may 
supplement questionnaire responses and provide a more detailed description of quality of life in 
HF.  
Earlier findings of in-hospital treatment for SDB has shown improvement of LVEF within days of 
using PAP therapy [17]. This has further implications for immediate treatment in the hospital 
setting. Dependent on the SDB type, patients would receive different PAP therapy devices 
immediately after screening. Previous studies have demonstrated the persistence of OSA in-
hospital and in the outpatient setting [17, 19-21, 71]. Additionally, this study has also 
demonstrated a persistence of CSA from in-hospital to post-discharge. The continued 
persistence of OSA and CSA could have greater implications for treatment initiation in-hospital 
as well as an evaluation of post-discharge outcomes.  
In summary, this study confirms a high prevalence of SDB in hospitalized patients for ADHF and 
is the first study that has evaluated an in-patient screening program with outcomes post-
discharge. There was no statistical significance between mean MLWHF scores; however, 
patients with SDB trended towards worsened quality of life. A larger sample is needed to detect 
differences in quality of life between SDB cohorts. Less than one third of patients indicated 
follow-up, which suggests modifications in the program for improved correspondence and 
patient education. While only two thirds of patients were notified of their SDB diagnosis six 
months post-discharge; this compares to a recently reported 4% diagnosis rate [49]. Despite on 
optimal medical treatment, a retrospective analysis of a separate CSA cohort demonstrated a 
continued persistence of central events post-discharge. Most importantly, this study supports 
the necessity of surveillance programs for screening and expedited treatment of SDB in ADHF.     
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Appendix A: Minnesota Living with Heart Failure Questionnaire  
Please indicate if you are receiving treatment for sleep apnea   Yes________No________ 
 
These questions1 concern how your heart condition has prevented you from living as you wanted 
during the last month. The items listed below describe different ways some people are affected.  If 
you are not sure an item does not apply to you or is not related to your heart condition, then circle 0 
(No) and go on to the next item.  If an item does apply to you, then circle the number rating how much 
it prevented you from living as you wanted. 
 
Did your heart condition prevent you from living as you wanted during the last month by: 
 No Very Little  Very Much 
1. Causing swelling in your ankles, legs, etc.? 
0 1 2 3 4 5 
2. Making you sit or lie down to rest during the day? 
0 1 2 3 4 5 
3. Making your walking about or climbing stairs difficult? 
0 1 2 3 4 5 
4. Making your working around the house or yard 
difficult? 
0 1 2 3 4 5 
5. Making your going places away from home difficult? 
0 1 2 3 4 5 
6. Making your sleeping well at night difficult? 
0 1 2 3 4 5 
7. Making your relating to or doing things with your 
friends or family difficult? 
0 1 2 3 4 5 
8. Making your working to earn a living difficult? 
0 1 2 3 4 5 
9. Making your recreational pastimes, sports, or hobbies 
difficult? 
0 1 2 3 4 5 
10. Making your sexual activities difficult? 
0 1 2 3 4 5 
11. Making you eat less of the foods you like? 
0 1 2 3 4 5 
12. Making you short of breath? 
0 1 2 3 4 5 
13. Making you tired, fatigued, or low on energy? 
0 1 2 3 4 5 
14. Making you stay in a hospital? 
0 1 2 3 4 5 
15. Costing you money for medical care? 
0 1 2 3 4 5 
16. Giving you side effects from medication? 
0 1 2 3 4 5 
17. Making you feel you are a burden to your family or 
friends? 
0 1 2 3 4 5 
18. Making you feel a loss of self-control in your life? 
0 1 2 3 4 5 
19. Making you worry? 
0 1 2 3 4 5 
20. Making it difficult for you to concentrate or remember 
things? 
0 1 2 3 4 5 
21. Making you feel depressed? 
0 1 2 3 4 5 
1
 Minnesota Living with Heart Failure™ Questionnaire © University of Minnesota 1986, Reproduced with permission.  
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Appendix B: Phone Call Algorithm  
 
 
 
* If it is related to access or location, we will take their 
information and schedule an appointment with a sleep 
clinic in their area. If there is an underlying issue of 
patient denial or disinterest in their results, we will skip 
to administering questions from the questionnaire  
Hello ________, my name is Jenny Hsieh and I 
am from Dr. Khayat’s office at the Ohio State 
University Medical Center in heart and sleep 
medicine. I was wondering if you had a few 
moments to talk?   
Reschedule call for 
another day 
Our records show that you were recently 
admitted at the hospital and had a sleep study 
done while you were here. I am calling to 
follow-up and see if you received a letter from 
us about your sleep study?  
NO 
NO 
If you would like, we would 
be more than happy to send 
you another letter  
Tell them the basics on what 
was in the letter and include 
education session 
Also in the letter, there was a recommendation to 
schedule another sleep study. Were you able to do 
so? 
Obtain information on where they had or will 
have the sleep study 
If possible we can schedule a follow 
up sleep study at the Medical Center. 
Depending on their reasoning for not 
getting a sleep study, we will address 
them accordingly.* 
Include education portion about the 
significance of their results and how SDB 
affects their diagnosis of heart failure. Did you 
have any questions about what was written in 
the letter? 
NO 
NO 
Answer questions or schedule appointment 
with Dr. Khayat to resolve any issues 
I was also wondering if you 
could answer a series of 
questions regarding how 
your condition has affected 
your day to day life?  
Administer the Minnesota Living 
with Heart Failure Questionnaire  
Thank you for your time. If you 
have any questions, please do not 
hesitate to call our office. 
NO 
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Table 1: Prevalence of Sleep Disordered Breathing in Acutely Decompensated Heart Failure  
 
 
 
  
  
 (*Due to lack of effort belt during the study, scoring result only indicated SDB) 
 
Table 2: Comparison of patient characteristics of Responders vs Non-Responders of the MLWHF Questionnaire 
 
 
  
 
 
Table 3: Characteristics of Patients based on SDB 
 
 
 
  
  
Type of Sleep Disordered Breathing # out of 105 sleep studies (%) 
OSA 65 (61.9%) 
CSA 14 (13.3%) 
Mixed 4 ( .9%) 
None 17 (16.2%) 
SDB* 5 (4.7%) 
Characteristics Responders Non-Responders P-Value 
Age 61.3 + 14.27 59.3 + 12.97 .469 
AHI 31.5 + 20.86 36.4 + 19.78 .227 
BMI (kg/m2) 30.6 + 7.43 33.4 + 10.28 .126 
Characteristics (n = 105) 
Positive SDB  
84% (n = 88) 
Negative SDB 
16% (n = 17) 
P-Value 
Age 60.5 + 13.8 60.0 + 15.05 .873 
EF 33.3 + 15.15 39.35 +  14.19 .130 
AHI 38.5 + 18.37 7.7 + 6.29 .000 
BMI (kg/m2) 31.93 + 8.98 30.94 + 8.13 .675 
MLWHF Score 35.98 + 23.34 23.50 +  29.91 .218 
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Figure 1: Follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients not mailed MLWHF 
Qaire or received phone call 
deceased or incarcerated  
(n=12) 
ADHF patients qualified 
for in-hospital sleep 
study between May and 
September 2010 (n=105) 
Patients mailed MLWHF 
Qaire and received a 
follow-up phone call  
 (n=93) 
Unsuccessful 
contact by phone  
 (n=31) 
Successful 
contact by phone  
 (n=62) 67% 
No follow-up with 
physician or sleep study  
 (n=42) 
Follow-up with physician 
or sleep study  
 (n=20) 32% 
Currently on treatment 
for SDB 
 (n=7) 
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